Tolerability and clinical efficacy of inhaled treprostinil in patients with group 1 pulmonary arterial hypertension

Medicine & Life Sciences

• treprostinil 100%
• Pulmonary Arterial Hypertension 70%
• Physicians 7%
• Epoprostenol 6%
• Vital Signs 6%
• Brain Natriuretic Peptide 6%
• United States Food and Drug Administration 5%
• Disease Management 5%
• Prostaglandins 5%
• Pulmonary Artery 5%
• Risk Assessment 5%
• Therapeutics 4%
• Arterial Pressure 4%
• Registries 4%
• Pressure 3%
• Heart 3%
• Demography 3%
• Blood Vessels 3%
• Lung 3%